Synlogic is a biopharmaceutical company that focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases. The Company was formed as a result of a reverse merger between Mirna Therapeutics and Synlogic. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The Сompany is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat immuno-oncology solid tumors.